Potential increased risk of cancer from commonly used medications: An umbrella review of meta-analyses

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 16-23

  Ioannidis, J P A ^a,b   Zhou, Y ^c   Chang, C Q ^d   Schully, S D ^d   Khoury, M J ^d,e   Freedman, A N ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Cancer; Meta analysis; Pharmacoepidemiology; Randomized trials; Review

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRHEUMATIC AGENT;

CANCER INCIDENCE; CANCER RISK; DRUG SAFETY; DRUG USE; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

CANCER; META-ANALYSIS; PHARMACOEPIDEMIOLOGY; RANDOMIZED TRIALS; REVIEW;

ANTIHYPERTENSIVE AGENTS; ANTIRHEUMATIC AGENTS; BONE DENSITY CONSERVATION AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; META-ANALYSIS AS TOPIC; NEOPLASMS; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84905371296     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt372     Document Type: Review

References (88)

1. Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: US prescription drug data for 2007-2008. NCHS Data Brief 2010; 42: 1-8.
2. Ioannidis JP. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 2009; 181: 488-493.
3. Monami M, Lamanna C, Marchionni N et al. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 2008; 31: 1455-1460.
4. Colmers IN, Bowker SL, Johnson JA. Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 2012; 38: 475-484.
5. Colmers IN, Bowker SL, Majumdar SR et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012; 184: E675-E683.
6. Dejgaard A, Lynggaard H, Rastam J et al. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a metaanalysis. Diabetologia 2009; 52: 2507-2512.
7. Monami M, Dicembrini I, Martelli D et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011; 27(Suppl 3): 57-64.
8. Dellavalle RP, Drake A, Graber M et al. Statins and fibrates for preventing melanoma. Cochrane Database Syst Rev 2005; CD003697.
9. Freeman SR, Drake AL, Heilig LF et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst 2006; 98: 1538-1546.
10. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008; 123: 899-904.
11. Alberton M, Wu P, Druyts E et al. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM 2012; 105: 145-157.
12. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008; 44: 2122-2132.
13. Alsheikh-Ali AA, Maddukuri PV, Han H et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007; 50: 409-418.
14. Alsheikh-Ali AA, Trikalinos TA, Kent DM et al. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 2008; 52: 1141-1147.
15. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
16. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
17. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 2001; 110: 716-723.
18. Bonovas S, Filioussi K, Flordellis CS et al. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007; 25: 3462-3468.
19. Bonovas S, Filioussi K, Sitaras NM. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol 2008; 103: 2646-2651.
20. Bonovas S, Filioussi K, Tsantes A et al. Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies. Br J Clin Pharmacol 2007; 64: 255-262.
21. Bonovas S, Filioussi K, Tsavaris N et al. Use of statins and breast cancer: a metaanalysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005; 23: 8606-8612.
22. Bonovas S, Filioussi K, Tsavaris N et al. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006; 24: 4808-4817.
23. Bonovas S, Nikolopoulos G, Filioussi K et al. Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. Eur J Epidemiol 2010; 25: 29-35.
24. Bonovas S, Sitaras NM. Does pravastatin promote cancer in elderly patients? A meta-analysis. CMAJ 2007; 176: 649-654.
25. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007; 120: 833-843.
26. Brugts JJ, Yetgin T, Hoeks SE et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: metaanalysis of randomised controlled trials. BMJ 2009; 338: b2376.
27. Cui X, Xie Y, Chen M et al. Statin use and risk of pancreatic cancer: a metaanalysis. Cancer Causes Control 2012; 23: 1099-1111.
28. Dale KM, Coleman CI, Henyan NN et al. Statins and cancer risk: a meta-analysis. JAMA 2006; 295: 74-80.
29. Mills EJ, Rachlis B, Wu P et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008; 52: 1769-1781.
30. Palmer SC, Craig JC, Navaneethan SD et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 263-275.
31. Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci 2007; 62: 879-887.
32. Saha SA, Kizhakepunnur LG, Bahekar A et al. The role of fibrates in the prevention of cardiovascular disease-a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007; 154: 943-953.
33. Stein EA, Corsini A, Gimpelewicz CR et al. Fluvastatin treatment is not associated with an increased incidence of cancer. Int J Clin Pract 2006; 60: 1028-1034.
34. Emberson JR, Kearney PM, Blackwell L et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012; 7: e29849.
35. Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590.
36. Sipahi I, Debanne SM, Rowland DY et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11: 627-636.
37. Bangalore S, Kumar S, Kjeldsen SE et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011; 12: 65-82.
38. Dong EW, Connelly JE, Borden SP et al. A systematic review and meta-analysis of the incidence of cancer in randomized, controlled trials of verapamil. Pharmacotherapy 1997; 17: 1210-1219.
39. Ross SD, Kupelnick B, Kumashiro M et al. Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis. J Hum Hypertens 1997; 11: 743-751.
40. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001; 22: 1343-1352.
41. Coleman CI, Baker WL, Kluger J et al. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 2008; 26: 622-629.
42. Sipahi I, Chou J, Mishra P et al. Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. Am J Cardiol 2011; 108: 294-301.
43. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens 2011; 29: 623-635.
44. Bongartz T, Sutton AJ, Sweeting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
45. Askling J, Fahrbach K, Nordstrom B et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 20: 119-130.
46. Gottlieb AB, Leonardi CL, Goffe BS et al. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006; 54: S92-100.
47. Bongartz T, Warren FC, Mines D et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009; 68: 1177-1183.
48. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68: 1136-1145.
49. Siegel CA, Marden SM, Persing SM et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 874-881.
50. Gaujoux-Viala C, Smolen JS, Landewe R et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1004-1009.
51. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010; CD008341.
52. Dommasch ED, Abuabara K, Shin DB et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011; 64: 1035-1050.
53. Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2011; 63: 1479-1485.
54. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012; 308: 898-908.
55. Pariser DM, Leonardi CL, Gordon K et al. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol 2012; 67: 245-256.
56. Wong AK, Kerkoutian S, Said J et al. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol 2012; 31: 631-636.
57. Stevenson M, Jones ML, De Nigris E et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005; 9: 1-160.
58. Lin T, Wang C, Cai XZ et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract 2012; 66: 399-408.
59. Heijl C, Harper L, Flossmann O et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 2011; 70: 1415-1421.
60. Robertson DJ, Burke CA, Schwender BJ et al. Histamine receptor antagonists and incident colorectal adenomas. Aliment Pharmacol Ther 2005; 22: 123-128.
61. van der Meer P, Groenveld HF, Januzzi JL, Jr et al. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009; 95: 1309-1314.
62. Ghalie RG, Mauch E, Edan G et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002; 8: 441-445.
63. Janghorbani M, Dehghani M, Salehi-Marzijarani M. Systematic review and meta-analysis of insulin therapy and risk of cancer. Horm Cancer 2012; 3: 137-146.
64. Li D, Tang H, Hassan MM et al. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 2011; 22: 189-197.
65. Deng L, Gui Z, Zhao L et al. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci 2012; 57: 1576-1585.
66. Zhang ZJ, Zheng ZJ, Kan H et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011; 34: 2323-2328.
67. Zhang ZJ, Zheng ZJ, Shi R et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97: 2347-2353.
68. Decensi A, Puntoni M, Goodwin P et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3: 1451-1461.
69. Soranna D, Scotti L, Zambon A et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012; 17: 813-822.
70. Taylor ML, Wells BJ, Smolak MJ. Statins and cancer: a meta-analysis of casecontrol studies. Eur J Cancer Prev 2008; 17: 259-268.
71. Corrao G, Scotti L, Bagnardi V et al. Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. Curr Drug Saf 2007; 2: 125-133.
72. Yoon C, Yang HS, Jeon I et al. Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. CMAJ 2011; 183: E1073-E1084.
73. Tressler CS, Wiseman RL, Dombi TM et al. Lack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literature. Br J Ophthalmol 2011; 95: 1490-1495.
74. Mariette X, Matucci-Cerinic M, Pavelka K et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70: 1895-1904.
75. Kashyap S, Moher D, Fung MF et al. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 2004; 103: 785-794.
76. Zreik TG, Mazloom A, Chen Y et al. Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res Treat 2010; 124: 13-26.
77. Gelman A, Weakliem D. Of beauty, sex and power. Am Scientist 2009; 97: 310-316.
78. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology 2008; 19: 640-648.
79. Ioannidis JP. Why most published research findings are false. PLoS Med 2005; 2: e124.
80. Peto R, Emberson J, Landray M et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008; 359: 1357-1366.
81. Ryan PB, Madigan D, Stang PE et al. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med 2012; 31: 4401-4415.
82. Feinstein AR. Scientific standards in epidemiologic studies of the menace of daily life. Science 1988; 242: 1257-1263.
83. Gerstein HC, Bosch J, Dagenais GR et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328. ORIGIN Trial Investigators
84. Sterne JA, Davey Smith G. Sifting the evidence-what's wrong with significance tests? BMJ 2001; 322: 226-231.
85. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005; 294: 218-228.
86. Ioannidis JP, Haidich AB, Pappa M et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001; 286: 821-830.
87. Papanikolaou PN, Christidi GD, Ioannidis JP. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 2006; 174: 635-641.
88. Ioannidis JP. The importance of potential studies that have not existed and registration of observational data sets. JAMA 2012; 308: 575-576.